Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada
03:59pm, Monday, 18'th Jul 2022 Zacks Investment Research
Moderna's (MRNA) mRNA-based COVID-19 jab, SpikeVax, receives approval from Health Canada for children aged six months through five years.
AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine
03:20pm, Monday, 18'th Jul 2022 Zacks Investment Research
AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.
After a 26% Drop, Should You Give Up on Novavax?
10:00am, Monday, 18'th Jul 2022 The Motley Fool
The shares are down -- but revenue and profit are on the rise.
Hold Pfizer Today With Catalysts For Further Growth Tomorrow
06:07am, Monday, 18'th Jul 2022 Investing.com
Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever
11:15am, Saturday, 16'th Jul 2022 The Motley Fool
Health and wealth; it doesn't get much better than that.
Super Bearish On Tesla Or Nvidia? Inverse, Leveraged ETFs Offer Investors New Opportunities
09:53pm, Friday, 15'th Jul 2022 Benzinga
New ETFs that offer investors the opportunity to be bullish or bearish on individual stocks hit the market this week. The new leveraged and inverse daily ETFs could be the first of many and could tak
2 Top Biotech Stocks to Buy Right Now
03:15pm, Friday, 15'th Jul 2022 The Motley Fool
Each of these companies has exceptional existing drug portfolios and drug pipelines.
This New Regulation Could Juice Pfizer Stock Even More
12:55pm, Friday, 15'th Jul 2022 The Motley Fool
Pharmacists will be able to prescribe Paxlovid now.
Novavax (NVAX) Down as EU Adds Side Effects to COVID Jab Label
12:28pm, Friday, 15'th Jul 2022 Zacks Investment Research
The administration of Novavax's (NVAX) COVID-19 vaccine leads to some cases of severe allergic reactions as well as skin problems, per a safety update issued by the EMA.
This Stock Is Down By 13% This Year: Here's Why It's a Buy
12:05pm, Friday, 15'th Jul 2022 The Motley Fool
The market may be undervaluing this drugmaker.
Pharma Stock Roundup: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds
11:48am, Friday, 15'th Jul 2022 Zacks Investment Research
Merck (MRK) buys co-development rights to prostate cancer candidate. FDA grants full approval to Pfizer's (PFE) COVID-19 vaccine for adolescents.
How Tax Loss Harvesting Works -- Turn Lemons Into Lemonade
11:00am, Friday, 15'th Jul 2022 The Motley Fool
Here's an investment strategy that allows you to purge losers without tax ramifications.
Novavax's protein-based vaccine approval fails to boost stock as demand in U.S. for shots and boosters remains low
10:27am, Friday, 15'th Jul 2022 MarketWatch
U.S. health regulators authorized the use of Novavax Inc.'s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines based on mRNA technology, but the move comes
Investors piling into healthcare ETFs points to defensive bets, ‘bottom-fishing’ in biotech
07:52pm, Thursday, 14'th Jul 2022 MarketWatch
In this week's ETF Wrap, healthcare ETFs take the spotlight as investors get defensive amid recession fears. But inflows also show that some investors may be “bottom-fishing” for beaten down stock
Novavax's (NVAX) Protein-Based COVID Jab Gets EUA in the US
03:06pm, Thursday, 14'th Jul 2022 Zacks Investment Research
Following the grant of emergency use authorization by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in the United States.
